Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732040 | 0.80 | NPC1 (0.59) | MAPTMEN1KMT2ANPC1LMNA | |
| SCHEMBL2759646 | 0.78 | NPC1 (0.58) | MAPTMEN1KMT2ANPC1CASP3 | |
| SCHEMBL28351671 | 0.78 | MAPT (0.60) | MAPTMEN1KMT2ANPC1LMNA | |
| SCHEMBL28172787 | 0.78 | LTA4H (0.51) | MAPTMEN1KMT2ANPC1LMNA | |
| SCHEMBL7831016 | 0.77 | LTB4R (0.47) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL4901279 | 0.73 | MAPT (0.71) | MAPTMEN1KMT2ANPC1LMNA | |
| SCHEMBL4901196 | 0.73 | MAPT (0.71) | MAPTMEN1KMT2ANPC1LMNA | |
| SCHEMBL7452503 | 0.72 | NPC1 (0.62) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL26649560 | 0.72 | MAPT (0.59) | MAPTMEN1KMT2ANPC1LMNA | |
| SCHEMBL25002894 | 0.71 | KMT2A (0.56) | MAPTMEN1KMT2ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358181-B1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1358181-A1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030199532-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | KERTESZ DENIS JOHN (US) | 2003-10-23 | — | — | US | disclosed |
| US-6552028-B2 | Inhibiting the binding of eotaxin to chemokine-3 (ccr-3) receptor; antiasthmatics | SYNTEX (U.S.A.) LLC | 2003-04-22 | — | — | US | disclosed |
| US-20020198255-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002050064-A1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
| EP-1131288-A1 | PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | disclosed |
| US-6166015-A | Pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000031032-A1 | PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199532-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | MAPT 3771/4885MEN1 4781/4885KMT2A 3324/4885 |
| US-20020198255-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | MAPT 3771/4885MEN1 4781/4885KMT2A 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.